about
Phased whole-genome genetic risk in a family quartet using a major allele reference sequenceIncorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Pharmacogenomics knowledge for personalized medicineFrom pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resourceClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6The BioPAX community standard for pathway data sharingSequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence DataIn silico comparative characterization of pharmacogenomic missense variants.Clinical interpretation and implications of whole-genome sequencing.Ribosomal dynamics inferred from variations in experimental measurementsMining biochemical information: lessons taught by the ribosome.PharmGKB summary: very important pharmacogene information for CYP4F2Using ODIN for a PharmGKB revalidation experiment.PharmGKB summary: phenytoin pathway.The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.
P50
Q21144940-FD591836-457C-4A67-9322-E430C80A4F75Q24567778-6903445C-BBCA-4FD8-AE7B-E90B04867A23Q24623166-84C3A3D9-1FA7-480D-870A-9096B3186CBEQ24632079-365A7282-43DD-45FD-8A43-305E8E7DE4B2Q26784507-DA5DB406-A08A-4503-BE97-9E3C1DDE939EQ27008360-84072CD7-C7F4-46EC-B03F-B3BE67C27C30Q27012807-C15DC8BB-1185-46F5-AD6E-AD4C01F3A069Q27987775-617D4388-C238-4AB6-B0C8-D475D57318BFQ28550151-CF3A6F0E-EDD5-4E0B-8C48-7CCAD55305E1Q30583473-86037D89-4196-4596-8E7D-542AB9737285Q33989890-91C42D9D-7DD2-4717-9701-45FA610B03B4Q34141707-BB1D64DE-2821-459A-B08C-420434A5893DQ34364231-31298891-79D2-4782-A9CF-B0460CC1B6B1Q34664072-C491FF23-9F99-4330-8609-582D983691E4Q35904823-F0381EDC-EBF1-426C-96A1-84041DD0E663Q35950546-846E55C8-1F7B-41C4-AE9C-B3118CFFE7BAQ37039082-4EA75AAF-05C9-4E24-9EF9-9690E1D973C4Q38445248-920D48D9-581C-40C5-BF79-2C560CB81938Q39173298-6B85FCD4-65BD-4B24-945A-061B71B703F0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michelle Whirl-Carrillo
@ast
Michelle Whirl-Carrillo
@en
Michelle Whirl-Carrillo
@es
Michelle Whirl-Carrillo
@nl
Michelle Whirl-Carrillo
@sl
type
label
Michelle Whirl-Carrillo
@ast
Michelle Whirl-Carrillo
@en
Michelle Whirl-Carrillo
@es
Michelle Whirl-Carrillo
@nl
Michelle Whirl-Carrillo
@sl
prefLabel
Michelle Whirl-Carrillo
@ast
Michelle Whirl-Carrillo
@en
Michelle Whirl-Carrillo
@es
Michelle Whirl-Carrillo
@nl
Michelle Whirl-Carrillo
@sl